Sign in →

Test ID HBOCZ BRCA1/BRCA2 Genes, Full Gene Analysis, Varies

Ordering Guidance

For a comprehensive hereditary cancer gene panel that includes BRCA1 and BRCA2 genes, consider 1 of the following tests:

-BRGYP / Hereditary Breast/Gynecologic Cancer Panel, Varies

-PANCP / Hereditary Pancreatic Cancer Panel, Varies

-PRS8P / Hereditary Prostate Cancer Panel, Varies


Testing for BRCA1 and BRCA2 genes as part of a customized panel is available. For more information see CGPH / Custom Gene Panel, Hereditary, Next-Generation Sequencing, Varies.


Targeted testing for familial variants (also called site-specific or known mutations testing) is available for these genes. For more information see FMTT / Familial Mutation, Targeted Testing, Varies. To obtain more information about this testing option, call 800-533-1710.

Shipping Instructions

Specimen preferred to arrive within 96 hours of collection.

Specimen Required

Patient Preparation: A previous bone marrow transplant from an allogenic donor will interfere with testing. Call 800-533-1710 for instructions for testing patients who have received a bone marrow transplant.

Specimen Type: Whole blood


Preferred: Lavender top (EDTA) or yellow top (ACD)

Acceptable: Any anticoagulant

Specimen Volume: 3 mL

Collection Instructions:

1. Invert several times to mix blood.

2. Send whole blood specimen in original tube. Do not aliquot.

Specimen Stability Information: Ambient (preferred) 4 days/Refrigerated


1. New York Clients-Informed consent is required. Document on the request form or electronic order that a copy is on file. The following documents are available :

-Informed Consent for Genetic Testing (T576)

-Informed Consent for Genetic Testing-Spanish (T826)

2. Molecular Genetics: Inherited Cancer Syndromes Patient Information (T519)

3. If not ordering electronically, complete, print, and send a Oncology Test Request (T729) with the specimen.

Useful For

Evaluating patients with a personal or family history suggestive of hereditary breast and ovarian cancer (HBOC) syndrome


Establishing a diagnosis of HBOC syndrome allowing for targeted cancer surveillance based on associated risks


Identifying variants within genes known to be associated with increased risk for HBOC syndrome allowing for predictive testing of at-risk family members


Therapeutic eligibility including poly adenosine diphosphate-ribose polymerase inhibitors in select cancer types

Method Name

Sequence Capture and Targeted Next-Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Sanger Sequencing.

Reporting Name

BRCA1/2 Full Gene Analysis

Specimen Type


Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time Special Container
Varies Varies

Reference Values

An interpretive report will be provided.

Day(s) Performed


Report Available

21 days to 28 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed, and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information


LOINC Code Information

Test ID Test Order Name Order LOINC Value
HBOCZ BRCA1/2 Full Gene Analysis 94191-4


Result ID Test Result Name Result LOINC Value
614719 Test Description 62364-5
614720 Specimen 31208-2
614721 Source 31208-2
614722 Result Summary 50397-9
614723 Result 82939-0
614724 Interpretation 69047-9
614725 Resources 99622-3
614726 Additional Information 48767-8
614727 Method 85069-3
614728 Genes Analyzed 48018-6
614729 Disclaimer 62364-5
614730 Released By 18771-6

Testing Algorithm

For more information see Breast, Gynecological and Prostate Cancer Testing Algorithm